09.18.24 -- Gamma-Delta T-Cell Therapy For AML

With AAV vectors rising to be the lead gene therapy delivery platform, how can manufacturers establish robust, scalable AAV processes that consistently deliver their target titers?

With the use of advanced in vitro models like Organ-Chips, researchers are gaining a better understanding of CAR T-cell therapy in the context of solid tumors.

Find answers to frequently asked questions about selecting appropriate controls, so you can confidently design your next plasmid-based experiment.

Learn how to set up a small-scale CAR T cell research workflow to simplify the transition to large-scale manufacturing in preclinical development. Using suitable tools early on is key.